Acute rejection episodic outcomes resulted from pre-transplant serum level of the soluble CD30 in kidney transplant recipients

CHEN Jiang-hua,LV Rong,HE Qiang,TIAN Jiong,WANG Hui-Ping,Jin Juan,CHEN Ying,MAO You-ying
DOI: https://doi.org/10.3760/j.issn:1001-7097.2005.08.012
2005-01-01
Abstract:Objective To investigate the influence of pretransplant soluble CD30 (sCD30) level on acute rejection episode in kidney transplant recipients. Methods This retrospective study included 707 allograft kidney transplant recipients from Dec 1998 to Aug 2003 and 40 healthy as controls. The recipients' pretransplant serum sample and post-transplant clinical data including acute rejection episodes were collected. The recipients were divided into low, median, high level sCD30 group according to their pretransplant sCD30 levels. sCD30 levels of the recipients and the controls were determined by ELJSA assay in duplicate. Results Kidney graft recipients had a significant increased pretransplant serum sCD30 content as comprared to healthy controls (P 0.01). The incidences of vascular rejection, cellular rejection and bordline increased positively with the pretransplant sCD30 level (all P 0.05). But the inversion rates of rejection were 100%, 90.6% and 78.6 in the low,median and high sCD30 groups,respectively. The sCD30 levels of vascular, cellular, bordline and clinical rejection groups were (198.95±76.09), (165.89±44.56), (172.94±74.22) and (161.23±64.87) U/ml,respectively, which were all higher than those of non-rejection group (all P 0.05). The sCD30 values were the highest in the vascular rejection. Multifactors logistic regression analysis indicated that the sCD30, PRA and CMV antigen were risk factors of acute rejection with odds ratio of 2.683, 2.384 and 2.065, respectively. Conclusion Pre-transplant serum level of sCD30 is a sensitive prognostic and risk factor for acute rejections.
What problem does this paper attempt to address?